Martin Marziniak

ORCID: 0000-0003-2128-1246
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Multiple Sclerosis Research Studies
  • Migraine and Headache Studies
  • Pain Mechanisms and Treatments
  • Peripheral Neuropathies and Disorders
  • Trigeminal Neuralgia and Treatments
  • Musculoskeletal pain and rehabilitation
  • Dermatology and Skin Diseases
  • Ophthalmology and Eye Disorders
  • Polyomavirus and related diseases
  • Systemic Lupus Erythematosus Research
  • Pain Management and Placebo Effect
  • Botulinum Toxin and Related Neurological Disorders
  • Neuroscience of respiration and sleep
  • Allergic Rhinitis and Sensitization
  • Fibromyalgia and Chronic Fatigue Syndrome Research
  • Urticaria and Related Conditions
  • Genetic Neurodegenerative Diseases
  • Amyotrophic Lateral Sclerosis Research
  • Pharmacological Effects of Natural Compounds
  • Long-Term Effects of COVID-19
  • Systemic Sclerosis and Related Diseases
  • Neurological disorders and treatments
  • Olfactory and Sensory Function Studies
  • Cell Adhesion Molecules Research
  • Reproductive System and Pregnancy

Isar-Amper-Klinikum München-Ost
2014-2024

Medizinische Hochschule Hannover
2009-2024

Ludwig-Maximilians-Universität München
2024

Jena University Hospital
2022

Centre Hospitalier Universitaire de Lille
2022

Hospital Arnau de Vilanova
2022

AB Science (France)
2022

Hospital Universitari de Girona Doctor Josep Trueta
2022

University of Girona
2022

Inserm
2022

Abstract Background The diagnostic and pathophysiological relevance of antibodies to aquaporin-4 (AQP4-Ab) in patients with neuromyelitis optica spectrum disorders (NMOSD) has been intensively studied. However, little is known so far about the clinical impact AQP4-Ab seropositivity. Objective To analyse systematically paraclinical features associated NMO Caucasians a stratified fashion according patients' serostatus. Methods Retrospective study 175 Caucasian (AQP4-Ab positive 78.3%). Results...

10.1186/1742-2094-9-14 article EN cc-by Journal of Neuroinflammation 2012-01-19

Experimental determination of pain sensitivity has received increasing attention because emerging clinical applications (including prediction postoperative and treatment response) scientific implications (e.g. it been proposed that above-average is a risk factor for the development chronic disorders). However, use experimental assessment on broad scale hampered by its requirements time, equipment human resources fact painful tested subject. Alternatives to testing are currently lacking. Here...

10.1016/j.pain.2009.06.020 article EN Pain 2009-08-11
Ingo Kleiter Anna Gahlen Nadja Borisow Katrin Fischer Klaus–Dieter Wernecke and 95 more Kerstin Hellwig Florence Pache Klemens Ruprecht Joachim Havla Tania Kümpfel Orhan Aktaş Hans‐Peter Hartung Marius Ringelstein Christian Geis Christoph Kleinschnitz Achim Berthele Bernhard Hemmer Klemens Angstwurm Jan‐Patrick Stellmann S. Schuster Martin Stangel Florian Lauda Hayrettin Tumani Christoph Mayer Markus Krumbholz Lena Zeltner Ulf Ziemann Ralf A. Linker Matthias Schwab Martin Marziniak Florian Then Bergh Ulrich Hofstadt‐van Oy Oliver Neuhaus Uwe K. Zettl Jürgen Faiss Brigitte Wildemann Friedemann Paul Sven Jarius Corinna Trebst Philipp Albrecht Ilya Ayzenberg Antonios Bayas Judith Bellmann‐Strobl F. Bischof Stefan Bittner Tobias Böttcher Johannes Brettschneider Mathias Buttmann Marcus D’Souza Barbara Ettrich Benedikt Frank Achim Gass Matthias Grothe Kersten Guthke Axel Haarmann Eva Marie Habedank F. Hoffmann Olaf Hoffmann Martin W. Hümmert Jutta Junghans Markku Kaste Barbara Kaulen Pawel Kermer Peter Kern Luisa Klotz Wolfgang Köhler E. Kolesilova Melanie Korsen Markus C. Kowarik Stefan Langel D.H. Lee Martin Liebetrau Felix Luessi Wael Marouf Stefanie Meister Arthur Melms Imke Metz Christoph Münch Sabine Niehaus Marc Pawlitzki Hannah Pellkofer Hans-Ulrich Puhlmann Refik Pul N. Retzlaf Arne Riedlinger Paulus Rommer Luise Röpke Kevin Rostásy Lioba Rückriem Christoph Ruschil Sven Schippling Makbule Şenel Joern P. Sieb Claudia Sommer Annette Spreer Andreas Steinbrecher Heike Stephanik Muriel Stoppe Marie Süße Björn Tackenberg

To analyze whether 1 of the 2 apheresis techniques, therapeutic plasma exchange (PE) or immunoadsorption (IA), is superior in treating neuromyelitis optica spectrum disorder (NMOSD) attacks and to identify predictive factors for complete remission (CR).This retrospective cohort study was based on registry German Neuromyelitis Optica Study Group, a nationwide network established 2008. It recruited patients with diagnosed according 2006 Wingerchuk criteria aquaporin-4...

10.1212/nxi.0000000000000504 article EN cc-by-nc-nd Neurology Neuroimmunology & Neuroinflammation 2018-09-27

Recently, a self-rating measure for pain perception based on imagined painful daily life situations, the Pain Sensitivity Questionnaire (PSQ), has been developed and shown to correlate with experimentally obtained intensity ratings in healthy subjects. Here, we assessed validity of PSQ investigation general (ie, outside site clinical pain) chronic patients. scores were 134 patients compared those 185 control In subgroup 46 patients, performed experimental testing site, including different...

10.1016/j.pain.2012.02.025 article EN Pain 2012-04-25

Background Experimental stress has been shown to have analgesic as well allodynic effect in animals. Despite the obvious negative influence of clinical pain conditions, stress-induced alteration sensitivity not tested humans so far. Therefore, we changes using an experimental stressor ten female healthy subjects and 13 patients with fibromyalgia. Methods Multiple sensory aspects were evaluated all participants help quantitative testing protocol before (60 min) after (10 90 inducing...

10.1371/journal.pone.0069460 article EN cc-by PLoS ONE 2013-08-07

To analyse predictors for relapses and number of attacks under different immunotherapies in patients with neuromyelitis optica spectrum disorder (NMOSD).This is a retrospective cohort study conducted neurology departments at 21 regional university hospitals Germany. Eligible participants were aquaporin-4-antibody-positive or aquaporin-4-antibody-negative NMOSD. Main outcome measures HRs from Cox proportional hazard regression models adjusted centre effects, important prognostic factors...

10.1136/jnnp-2017-315603 article EN cc-by-nc Journal of Neurology Neurosurgery & Psychiatry 2017-06-01

Journal Article Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical cutaneous neuropathy Get access B. Schuhknecht, Schuhknecht Departments Dermatology Search for other works by this author on: Oxford Academic Google Scholar M. Marziniak, Marziniak Neurology, Competence Center Chronic Pruritus, University Hospital Münster, Von‐Esmarch‐Str. 58, D‐48149 Germany A. Wissel, Wissel N.Q. Phan, Phan D. Pappai, Pappai J....

10.1111/j.1365-2133.2011.10306.x article EN British Journal of Dermatology 2011-03-17
Paul O’Connor Cristoforo Comi Mark S. Freedman Aaron Miller Ludwig Kappos and 95 more Jean‐Pierre Bouchard Christine Lebrun‐Frénay Jan Mareš Myriam Bénamor Karthinathan Thangavelu Jinjun Liang Philippe Truffinet Victoria Lawson Jerry S. Wolinsky E. Maida Eduard Auff Franz Fazekas Thomas Berger Virender Bhan J-P Bouchard Pierre Duquette Mark S. Freedman François Grand’Maison M. Kremenchutzky Caitlin Bourque Ruth Ann Marrie Maria Melanson D. Patry Paul O’Connor Joël Oger Mark Stefanelli François Jacques Pablo Venegas Manoel Miranda N. Barrientos E Tenhamm Sergio Gloger Gernot Rohde Jan Mareš Jette Lautrup Frederiksen Egon Stenager Sulev Haldre Katrin Gross‐Paju Irina Elovaara M-L Sumelahti J-P Erälinna J-P Erälinna Martti Färkkilâ Hanna Harno Mauri Reunanen T. Jolma Cyrille B. Confavreux William Camu Pierre Clavelou Laurent Magy Marc Debouverie Gilles Edan Christine Lebrun‐Frénay T. Moreau Jean Pelletier E Roullet Sonia Alamowitch M. Clanet Patrick Hautecœur Philippe Damier L. Rumbach Andrew Chan Sebastian Schimrigk J. Haas Eckart Lensch Hans‐Christoph Diener Volker Limmroth D. Anders Martin Berghoff Patrick Oschmann Martin Stangel Martin Berghoff Achim Frese Reinhard Kiefer Martin Marziniak Uwe K. Zettl E. Stark K. Jendroska Gerd Reifschneider Mauro Amato Giacomo P. Comi V. Cosi Pamela Gallo Claudio Gasperini Angelo Ghezzi Maria Trojano Carlo Pozzilli E. Montanari Cees Zwanikken P.J.H. Jongen E.Th.L. van Munster Raymond Hupperts Bert W.M. Anten E.A.C.M. Sanders E. Celius

<h3>Objective:</h3> To report safety and efficacy outcomes from up to 9 years of treatment with teriflunomide in an extension (NCT00803049) the pivotal phase 3 Teriflunomide Multiple Sclerosis Oral (TEMSO) trial (NCT00134563). <h3>Methods:</h3> A total 742 patients entered extension. Teriflunomide-treated continued original dose; those previously receiving placebo were randomized 1:1 14 mg or 7 mg. <h3>Results:</h3> By June 2013, median (maximum) exposure exceeded 190 (325) weeks per...

10.1212/wnl.0000000000002441 article EN cc-by-nc-nd Neurology 2016-02-11

Despite recent advances in multiple sclerosis (MS) care, many patients only infrequently access health care services, or are unable to them easily, for reasons such as mobility restrictions, travel costs, consultation and treatment time constraints, a lack of locally available MS expert services. Advances mobile communications have led the introduction electronic (eHealth) technologies, which helping improve both quality As Internet is now readily accessible through smart devices, most...

10.2196/rehab.7805 article EN cc-by JMIR Rehabilitation and Assistive Technologies 2018-04-24

Environmental conditions (eg, latitude) play a critical role in the susceptibility and severity of many autoimmune disorders, including multiple sclerosis (MS). Here, we investigated mechanisms underlying beneficial effects immune regulatory processes induced skin by moderate ultraviolet B (UVB) radiation on central nervous system (CNS) autoimmunity.Effects UVB light were analyzed murine model CNS autoimmunity (experimental encephalomyelitis). Additionally, patients with relapsing-remitting...

10.1002/ana.24165 article EN Annals of Neurology 2014-04-27

Treatment of neuropathic pain (NP) symptoms associated with multiple sclerosis (MS) is frequently insufficient. Yet, cannabis still rarely offered for treatment pain. This clinical trial aimed at showing the positive benefit-risk ratio dronabinol. Two hundred forty MS patients central NP entered a 16-weeks placebo-controlled phase-III study followed by 32-weeks open-label period. One continued therapy overall up to 119 weeks. Primary endpoint was change intensity on 11-point Numerical Rating...

10.1159/000481089 article EN cc-by-nc-nd European Neurology 2017-01-01
Patrick Vermersch Luís Brieva Robert J. Fox Friedemann Paul Lluís Ramió‐Torrentà and 95 more Matthias Schwab Alain Moussy Colin D. Mansfield Olivier Hermine Maciej Maciejowski Nassima Hecham Norma Deri Jasminka Djelilović-Vranić Ivan Milanov Penko Shotekov Gregg Blevins J Girard Yves Lapierre William Camu Giovanni Castelnovo Pierre Clavelou Patrick Hautecœur Martin Marziniak Christoph Mayer Patrick Oschmann Gerd Reifschneider I. Schoell Björn Tackenberg Florian Then Bergh Ν. Fakas Nikolaos Grigoriadis D. Kalochristianakis Dimos D. Mitsikostas Anastasios Orologas Antonios Tavernarakis Thomas Thomaidis Krisztina Kovács K Mátyás Pálma Piros Mária Sátori K.J.S. Anand Alexander L. Shifrin Krzysztof Banaszkiewicz Robert Bonek M. Chahwan M. Czernichowska - Kotiuszko Lidia Darda-Ledzion J. D. Wojcik M Dziki Ewa Krzystanek Marianna Kulka Paweł Lisewski Marcin Ratajczak Andrzej Szczudlik Jarosław Szczygieł Małgorzata Pańczyk-Tomaszewska Jacek Wójcik Daniel Zielonka M. Chiru Swaroopa Deme S Mănescu S.A. Nica Christian Popescu Szabolcs Szatmári A. L. Fedyanin N A Malkova D.V. Popov Л. И. Волкова Vorob'eva Ov M Brozman Andrea Cimprichová P. Cuchran Ladislav Gurcik Georgi Krastev I. Lisá M. Nyeky J. Poljaková Peter Turčáni Adaani Frost Josef G. Heckmann Eduardo Agüera Francisco Coret Antonio Escartín Victoria Fernández JR. Ara Callizo Greg S. Martin José Rodríguez M. Martinez Gines Daniel Muñoz Javier Olascoaga José M. Prieto Cristina Ramo‐Tello Samir Belal S. Ben Ammou Mahbouba Frih-Ayed Riadh Gouider Chokri Mhiri Ridha Mrissa Alla Cherkez H. Chmyr

Masitinib is a selective tyrosine kinase inhibitor, targeting innate immune cells (mast and microglia) that are involved in the pathophysiology of progressive multiple sclerosis (MS). Study AB07002 assessed oral masitinib patients with MS who were progressing but not clinically active.

10.1212/nxi.0000000000001148 article EN cc-by-nc-nd Neurology Neuroimmunology & Neuroinflammation 2022-02-21

Tumor necrosis factor alpha (TNF) may be involved in the pathogenic mechanisms of neuropathic pain by affecting endothelial cells and upregulation receptor sensitivity afferent nerve fibers. To test hypothesis that TNF plays a role vascular changes pain-related behavior an experimental painful neuropathy rats produced tying loosely constrictive ligatures around one sciatic nerve, we investigated effect thalidomide, selective blocker TNF-production activated macrophages. In which treatment...

10.1016/s0304-3959(97)00154-1 article EN Pain 1998-01-01

Etanercept, a recombinant tumor necrosis factor receptor (p75)-Fc fusion protein competitively inhibits factor-alpha (TNF). Etanercept has been successfully used in patients with rheumatoid arthritis, where it reduces pain and inflammation. Because locally produced proinflammatory cytokines play role after nerve injury, we investigated whether etanercept can reduce hyperalgesia an animal model of painful neuropathy, the chronic constriction injury sciatic nerve. C57BL/6 mice received or sham...

10.1046/j.1529-8027.2001.01010.x article EN Journal of the Peripheral Nervous System 2001-06-01

Thalidomide reduces thermal hyperalgesia and mechanical allodynia in chronic constrictive sciatic nerve injury (CCI). Since thalidomide mainly inhibits tumor necrosis factor alpha (TNF-α) synthesis with less well defined effects on other cytokines, we investigated the effect of drug expression proinflammatory cytokines TNF-α, interleukin-1β (IL-1β) interleukin 6 (IL-6), anti-inflammatory cytokine interleukin-10 (IL-10) lesioned rat nerve. The increase endoneurial TNF-α during first week...

10.1016/s0304-3959(00)00333-x article EN Pain 2000-12-01

Background In neurological diseases presenting with a plethora of symptoms, the value bodily functions for given patient might be guide clinical management. Multiple sclerosis (MS) is paradigmatic in this respect, and little known about different patients their physicians' perceptions. Methods multicenter study, 171 relapsing-remitting multiple (RRMS), 61% clinically active disease within last 2 years were followed over up to 3 yearly study physician rated on perceived 13 via priority list....

10.1111/ane.12881 article EN Acta Neurologica Scandinavica 2017-12-03

<h3>Objective</h3> To evaluate the efficacy of an evidence-based patient information programme aiming to increase informed choice in patients with early multiple sclerosis (MS). <h3>Background</h3> Patients MS face a number uncertainties concerning diagnosis, prognosis and effectiveness immunotherapy. Prior studies suggest that combined group education can promote patients. <h3>Methods</h3> A 12-month, six-centre, double-blind randomised controlled clinical trial 192 diagnosis confirmed...

10.1136/jnnp-2013-306441 article EN Journal of Neurology Neurosurgery & Psychiatry 2013-10-08
Coming Soon ...